Industries > Pharma > Attention Deficit Hyperactivity Disorder Drugs Market Forecast to 2029

Attention Deficit Hyperactivity Disorder Drugs Market Forecast to 2029

Amphetamine, Methylphenidate Hydrochloride, Dexymethylphenidate, Lisdexamfetamine, Atomoxetine, Guanfacine, Clonidine, Stimulants, No-stimulants, Adults, Children, Retail Pharmacy, Hospital Pharmacy

PUBLISHED: 31 October 2019
PAGES: 151
PRODUCT CODE: PHA0575
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0575 Categories: , Tag:

The global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market is estimated to have reached $13.40bn in 2018 and is expected to grow at a CAGR of 4.43% in the first half of the forecast period. The stimulants submarket held 75% of the global Attention Deficit Hyperactivity Disorder (ADHD) Market in 2018.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 151-page report you will receive 124 charts– all unavailable elsewhere.

The 151-page report provides clear detailed insight into the ADHD market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029

• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029 by leading drugs:
• Amphetamine
• Methylphenidate
• Lisdexamfetamine
• Dexmethylphenidate
• Atomoxetine
• Guanfacine
• Clonidine
• Other Drugs

Attention Deficit Hyperactivity Disorder Drugs Market Forecast to 2029

• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029 by drug type:
• Stimulants
• Non-stimulants

• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029 by patient type:
• Adult
• Children

• Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market forecasts to 2029 national market:
• The U.S.
• Germany
• France
• The U.K.
• Italy
• Spain
• China
• Japan
• India
• Brazil
• Russia

• This report discusses the selected leading companies:
• Eli Lilly
• Johnson and Johnson
• Lupin Limited
• Mallinckrodt & Co.
• Neos Therapeutics
• Pfizer Inc.
• Purdue Pharma L.P.
• Takeda Pharmaceuticals

• This report provides a SWOT Analysis and Porter’s Five Forces Analysis of the Attention Deficit Hyperactivity Disorder Drugs market.

• Key questions answered by this report:
• How is the ADHD market evolving?
• What is driving and restraining the ADHD market?
• What are the market shares of each segment of the overall ADHD market in 2018?
• How will each ADHD submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each ADHD’s submarket develop from 2018 to 2029?
• Which individual products will prevail and how will these shifts be responded to?
• What will be the main driver for the overall market from 2018 to 2029?
• How will political and regulatory factors influence the regional markets and submarkets?
• Will leading national vaccine markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2029 and which geographical region will lead the market in 2029?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve during the period between 2018 and 2029?

Visiongain’s study is intended for anyone requiring commercial analyses for the Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market. You find data, trends and predictions.

Buy our report today Attention Deficit Hyperactivity Disorder Drugs Market Forecast: Amphetamine, Methylphenidate Hydrochloride, Dexymethylphenidate, Lisdexamfetamine, Atomoxetine, Guanfacine, Clonidine, Stimulants, No-stimulants, Adults, Children, Retail Pharmacy, Hospital Pharmacy.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Attention Deficit Hyperactivity Disorder Drugs Market Forecast to 2029


Download sample pages

Complete the form below to download your free sample pages for Attention Deficit Hyperactivity Disorder Drugs Market Forecast to 2029


Latest Pharma news

Visiongain Publishes Single-Cell Analysis Market Report 2022-2032

The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.

26 May 2022

READ

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022

READ

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022

READ

Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022

READ

Categories